AletheiaHQ
DIR-E7-5MW-O4IS/LVL 5·Leveraged OperationsHigh-leverage, capital-intensive cell operations. Requires fronted capital or established legal infrastructure. Examples: fronting $10k to lease warehouse space ahead of a known logistics fracture; forming a joint entity to secure and sub-license a dormant government patent for recurring royalties./75% confidence
Return to Directory

Secure Manufacturing Process IP via Provisional Patent & Exclusive Licenseback

Organization
CYTROGEN's focus on material composition patents rather than manufacturing scale-up methods
Sector
GMP contract manufacturers seeking exclusive partnerships with novel biomaterial technologies
Location
Location unspecified
// Venture Capital// Biotech// Negotiation// Materials Science// Compliance// IP// Manufacturing// Health Policy & Regulation

Executive Context

NSF awarded $305K SBIR Phase I funding to CYTROGEN for Gelatrix, a light-curable bone adhesive, creating a research-funded entity with technical validation capital but zero commercial infrastructure, manufacturing partnerships, or market access pathways.

Catalyst / Timing

CYTROGEN's SBIR project focuses on material properties (light-curable, osteoinductive) but lacks protected manufacturing processes for GMP-scale production. Academic researchers typically patent compositions, not scalable manufacturing methods, creating an IP gap between lab synthesis and commercial production.

Projected Yield

5% royalty on projected $50-100M market → $2.5-5M annual royalty stream at scale

Structural Friction

• Vulnerability: CYTROGEN's SBIR project focuses on material properties (light-curable, osteoinductive) but lacks protected manufacturing processes for GMP-scale production. Academic researchers typically patent compositions, not scalable manufacturing methods, creating an IP gap between lab synthesis and commercial production. • Capital yield: 5% royalty on projected $50-100M market → $2.5-5M annual royalty stream at scale • Resource capture: Provisional patent portfolio on GMP manufacturing process • Sovereignty yield: Control over manufacturing partner selection for novel bone adhesive technology • Required vectors: Vector: Intellectual Property Law, Vector: Medical Device Manufacturing, Vector: Contract Negotiation & Deal Structuring

Required Capabilities

  • Vector: Intellectual Property Law

    Primary executor: Phase 1: Manufacturing Method Gap Analysis: Hire contract patent searcher via Upwork to analyze all patents filed by Kha

  • Vector: Medical Device Manufacturing

    Supporting vector for: Secure Manufacturing Process IP via Provisional Patent & Exclusive Licenseback

  • Vector: Contract Negotiation & Deal Structuring

    Supporting vector for: Secure Manufacturing Process IP via Provisional Patent & Exclusive Licenseback

Execution Protocol

Execution Protocol Locked

A one-time payment of $1799 unlocks the exact wedge, required assets, and step-by-step execution parameters yours forever, no subscription.

This report is synthesized intelligence, not verified instruction. Always confirm against the primary source before acting. Review the full legal disclaimer before proceeding.